Vanguard Personalized Indexing Management LLC Has $5.06 Million Stock Position in Becton, Dickinson and Company $BDX

Vanguard Personalized Indexing Management LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 25.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,999 shares of the medical instruments supplier’s stock after acquiring an additional 5,506 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Becton, Dickinson and Company were worth $5,055,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. RiverGlades Family Offices LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $344,000. Strs Ohio boosted its stake in Becton, Dickinson and Company by 31.7% in the 3rd quarter. Strs Ohio now owns 301,430 shares of the medical instruments supplier’s stock valued at $56,419,000 after buying an additional 72,626 shares in the last quarter. Covea Finance lifted its holdings in shares of Becton, Dickinson and Company by 10.7% during the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after acquiring an additional 7,610 shares during the period. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $983,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BDX. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Bank of America raised their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Finally, Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $209.00.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable March 31; record date March 10), implying a ~2.1% yield — supports income investors and signals cash‑flow confidence. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
• Positive Sentiment: Board authorized an additional $10M share buyback and the company says it has completed ~$250M of repurchases in FY26 to date — modest on a large market cap but signals management sees shareholder value in buybacks. RTT News – Stock Buybacks
• Positive Sentiment: Spin‑off of BD’s Biosciences & Diagnostic Solutions business is advancing: company set a February 5 record date and Waters shareholders approved the combination — this corporate‑restructuring could unlock value and reshape BD’s growth profile. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters shareholders approved the combination with BD’s biosciences unit, removing a key approval hurdle and making the transaction timing clearer for investors. Waters Shareholders Approve Combination
• Positive Sentiment: Product and tech update — BD launched BD Research Cloud 7.0 with an AI-powered Horizon Panel Maker for advanced flow cytometry, supporting differentiation in lab workflow automation and data analytics. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD scheduled an audio webcast to announce Q1 FY2026 results — earnings and guidance will be the next major catalyst and could increase volatility. BD to Announce Financial Results for its First Quarter of Fiscal 2026
• Neutral Sentiment: Several analyst/feature pieces highlight BDX as a value and momentum name and compare it to peers — useful for sentiment but not new company fundamentals. Why Becton Dickinson (BDX) is a top value stock

Becton, Dickinson and Company Trading Up 0.4%

BDX traded up $0.86 during mid-day trading on Wednesday, reaching $204.26. The stock had a trading volume of 120,835 shares, compared to its average volume of 1,676,365. The firm’s fifty day simple moving average is $197.87 and its two-hundred day simple moving average is $190.90. The stock has a market capitalization of $58.20 billion, a P/E ratio of 35.00, a P/E/G ratio of 2.25 and a beta of 0.23. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.92 by $0.04. The business had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,605 shares of company stock valued at $524,643 in the last ninety days. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.